PRISM MarketView published an exclusive Q&A with Yoshiyuki Aikawa, Chairman and CEO of SBC Medical Group Holdings, discussing the company's transition from a domestic Japanese platform to a globally scalable model. The interview highlights SBC Medical's recent operational inflection, strategic U.S. market entry, and long-term growth initiatives.
The company reported improving unit economics, with fourth-quarter average revenue per visit increasing 11% year over year to $316. This signals a recovery following a multi-quarter compression trend. "The recovery in average revenue per visit is the clearest signal of improving unit economics," according to the discussion. Despite a revenue decline in 2025 due to intentional structural changes, net income grew 9% and margins remained intact.
SBC Medical's expansion into the United States market represents a significant strategic move. The company entered through a minority investment in OrangeTwist, a premium medspa platform. Management believes its system-driven approach to clinical quality, customer retention, and operational efficiency can differentiate the platform in the fragmented U.S. aesthetic market. "Few operators have built systems that replicate quality at scale. That is the system we are introducing into the U.S. market," Aikawa stated in the interview.
The company operates with a capital-light business model that has generated EBITDA margins above 40% across a network of 283 locations and 6.63 million annual patient visits. This financial discipline is supported by a strong balance sheet with $164 million in cash and low leverage, providing flexibility for mergers and acquisitions and continued expansion.
Long-term growth initiatives include AI-driven operational infrastructure and the expansion of SBC Wellness 2.0 into Japan's $34 billion longevity market. The full Q&A, published by PRISM MarketView, is available at https://prismmarketview.com/q4-2025-earnings-beat-orangetwist-partnership-update-and-growth-strategy/. The company's latest earnings presentation can be viewed at https://youtu.be/CUujUbs7vo8.
For business and technology leaders, SBC Medical's progress demonstrates how established international healthcare operators can leverage operational efficiency and system standardization to enter new markets. The company's focus on unit economics recovery while maintaining high margins provides a case study in disciplined growth during transitional periods. The U.S. expansion through OrangeTwist represents a strategic entry point into the competitive American aesthetic market, where SBC's operational systems could create competitive advantages in quality replication at scale.
